Evolving understanding of the CLL genome.

Semin Hematol
Authors
Keywords
Abstract

Over the past few years, massively parallel sequencing technologies have revealed with high resolution the tremendous genetic and epigenetic heterogeneity in chronic lymphocytic leukemia (CLL). We have learned how the molecular architecture differs not only between affected individuals but also within samples and over time. These insights have catalyzed our understanding of the pathobiology of CLL and point to critical signaling pathways in the development and progression of the disease. Several key driver alterations have been identified, which serve to refine prognostic schemata but also to inspire the development of new therapeutic strategies. Ongoing advances in technology promise to further elucidate the molecular basis of CLL, and this knowledge is anticipated to aid us in understanding and addressing the clinical challenge presented by the vast variability in the clinical course of patients with CLL.

Year of Publication
2014
Journal
Semin Hematol
Volume
51
Issue
3
Pages
177-87
Date Published
2014 Jul
ISSN
1532-8686
DOI
10.1053/j.seminhematol.2014.05.004
PubMed ID
25048782
PubMed Central ID
PMC4107366
Links
Grant list
1R01HL103532-01 / HL / NHLBI NIH HHS / United States
R01 CA182461 / CA / NCI NIH HHS / United States
R01 HL103532 / HL / NHLBI NIH HHS / United States
R01 CA155010 / CA / NCI NIH HHS / United States
1R01CA155010-01A1 / CA / NCI NIH HHS / United States
R01 HL116452 / HL / NHLBI NIH HHS / United States